Comparison of the ocular surface microbiota in meibomian gland dysfunction patients and healthy subjects

Rachadapiseksompoch fund0 sites78 target enrollmentFebruary 21, 2021

Overview

No summary available.

Registry

who.int

Start Date

February 21, 2021

End Date

November 30, 2021

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

Rachadapiseksompoch fund

•MGD patients
•1\)Adult patients aged 18\-80 years with a chief complaint of one of the following symptoms: dryness, foreign body sensation, burning, or tearing.
•2\)A diagnosis of MGD with two or more of the following signs : redness or thickening of the lid margin, telangiectasia, reduced or no secretions, poor quality secretions, and gland obstruction.
•3\)If both eyes are involved, the investigator (U.R.) will randomly select only one eye.
•Healthy controls
•1\)No chief complaint of any dry eye symptoms or tear break up time (TBUT) is equal to or longer than 5 seconds without obvious dry eye symptoms.
•2\)MG associated assessments do not meet the criteria for diagnosis of MGD.
•3\)Corneal staining is negative
•4\)If both eyes are involved, the investigator (U.R.) will randomly select only one eye.

•Both MGD patients and Healthy controls
•1\)Use topical or systemic antibiotics within the past month
•2\)Use other topical eye drops within 3 months (other than artificial tears)
•3\)Use contact lenses within the past month
•4\)Active allergies, infections, or inflammatory diseases of the ocular surface unrelated to dry eye or MGD
•5\)A history of ocular trauma or surgery within one year
•6\)Has systemic diseases affecting the ocular surface
•7\)Healthcare workers